[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU1029895A - Liposome solutions - Google Patents

Liposome solutions

Info

Publication number
AU1029895A
AU1029895A AU10298/95A AU1029895A AU1029895A AU 1029895 A AU1029895 A AU 1029895A AU 10298/95 A AU10298/95 A AU 10298/95A AU 1029895 A AU1029895 A AU 1029895A AU 1029895 A AU1029895 A AU 1029895A
Authority
AU
Australia
Prior art keywords
liposome solutions
liposome
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU10298/95A
Other versions
AU699142B2 (en
Inventor
Michel Fernex
Hans Steffen
Andreas Supersaxo
Frank-Peter Thiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU1029895A publication Critical patent/AU1029895A/en
Application granted granted Critical
Publication of AU699142B2 publication Critical patent/AU699142B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10298/95A 1994-01-25 1995-01-19 Liposome solutions Ceased AU699142B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH213/94 1994-01-25
CH21394 1994-01-25

Publications (2)

Publication Number Publication Date
AU1029895A true AU1029895A (en) 1995-08-03
AU699142B2 AU699142B2 (en) 1998-11-26

Family

ID=4181848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10298/95A Ceased AU699142B2 (en) 1994-01-25 1995-01-19 Liposome solutions

Country Status (10)

Country Link
EP (1) EP0664117A1 (en)
JP (1) JPH07206713A (en)
KR (1) KR950031041A (en)
CN (1) CN1111125A (en)
AU (1) AU699142B2 (en)
BR (1) BR9500296A (en)
CA (1) CA2140701A1 (en)
NZ (1) NZ270362A (en)
RU (1) RU95101041A (en)
ZA (1) ZA95404B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
CN102048740B (en) * 2010-12-02 2012-06-13 郝志艳 Liposome injection prepared from ceftriaxone sodium tazobactam sodium medicinal composition
WO2013036783A2 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN102973568B (en) * 2012-12-10 2014-08-27 江苏开元医药化工有限公司 Preparation method of liposome of medicine composition of ceftriaxone sodium and sulbactam sodium
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN112791074B (en) * 2021-03-17 2022-10-04 中山大学 Application of houttuynin and/or sodium new houttuynin in preparing NDM-1 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
EP0479582A1 (en) * 1990-10-03 1992-04-08 Alexander Karl Friedrich Wilhelm Overweg Restorative periodontal technique

Also Published As

Publication number Publication date
AU699142B2 (en) 1998-11-26
JPH07206713A (en) 1995-08-08
BR9500296A (en) 1995-10-17
EP0664117A1 (en) 1995-07-26
NZ270362A (en) 1996-10-28
KR950031041A (en) 1995-12-18
CN1111125A (en) 1995-11-08
RU95101041A (en) 1997-02-27
ZA95404B (en) 1995-07-25
CA2140701A1 (en) 1995-07-26

Similar Documents

Publication Publication Date Title
AU3613695A (en) Liposomal agents
AU3304795A (en) Bisresorcinyltriazines
AU2832295A (en) Cytoanalyzer
AU3304995A (en) 2-Hydroxyphenyltriazines
AU2837895A (en) Thiazine- or thiazepine-derivatives
AU4131596A (en) Polyglycomers
AU4044795A (en) Handleset
AU699142B2 (en) Liposome solutions
AU2308295A (en) Heterocyclylbenzonitriles
AU1963395A (en) Boom-structure
AU4029295A (en) Thienopyridones
AU2083495A (en) Liposome with increased retention volume
AU7469594A (en) Poop-scoop
AU3166195A (en) Acylimidazopyridines
AU4590996A (en) Boekomslag
AUPM365494A0 (en) Pre-chiller
AU3265895A (en) Liposome preparation
AU3166095A (en) Benzylimidazopyridines
AU2411395A (en) Hydrocopter
AU1603595A (en) Meso-azanoradamantanes
AU3446995A (en) Biodestumping
AU3417395A (en) Hydro-ethano-indeno-pyridines
AUPM374794A0 (en) Compartmentalizer
AU693176C (en) Campervan
AU658811B3 (en) Bum-bag

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired